References
- U.S. Xyrem Multi‐Center Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003; 41: 131–135
- Hornfeldt C S. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not produce withdrawal symptoms. Abstract. J Toxicol Clin Toxicol 2001; 39: 516
- Galloway G P, Frederick S L, Staggers F E, Gonzales M, Stalcup S A, Smith D E. Gamma‐hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92: 89–96, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dyer J E, Roth B, Hyma B A. Gamma‐hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37: 147–153, [PUBMED], [INFOTRIEVE], [CROSSREF]
- McDaniel C H, Miotto K A. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoact Drugs 2001; 33: 143–149
- Craig K, Gomez H F, McManus J L, Bania T C. Severe gamma hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18: 65–70, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zvosec D L, Smith S W. Unsupported “efficacy” claims of gamma hydroxybutyrate (GHB). Letter to the editor. Acad Emerg Med 2003; 10: 95–96, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Winker M A. The need for concrete improvement in abstract quality. JAMA 1999; 281: 1129–1130, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zvosec D L, Smith S W, McCutcheon J R, Spillane J, Hall B J., Peacock E A. Adverse events, including death, associated with the use of 1,4 butanediol. N Engl J Med 2001; 344: 87–94, [PUBMED], [INFOTRIEVE], [CROSSREF]